Liaoning Cheng Da Co Ltd

SHG:600739 China Medical Distribution
Market Cap
$2.54 Billion
CN¥18.62 Billion CNY
Market Cap Rank
#6073 Global
#886 in China
Share Price
CN¥12.17
Change (1 day)
-1.14%
52-Week Range
CN¥9.48 - CN¥13.34
All Time High
CN¥30.21
Categories
Companies in China Medical Distribution
About

Liaoning Cheng Da Co., Ltd. engages in biopharmaceutical, financial investment, supply chain, energy development, and other businesses in China and internationally. The company is involved in the import and export of textiles, and clothing, as well as the trade of bulk commodities, such as coal, steel, and aquatic products; and oil shale mining, shale oil production, and sale business. It also of… Read more

Liaoning Cheng Da Co Ltd (600739) - Net Assets

Latest net assets as of September 2025: CN¥33.56 Billion CNY

Based on the latest financial reports, Liaoning Cheng Da Co Ltd (600739) has net assets worth CN¥33.56 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥49.17 Billion) and total liabilities (CN¥15.61 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥33.56 Billion
% of Total Assets 68.25%
Annual Growth Rate 20.07%
5-Year Change 29.5%
10-Year Change 73.29%
Growth Volatility 32.76

Liaoning Cheng Da Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Liaoning Cheng Da Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Liaoning Cheng Da Co Ltd (1993–2024)

The table below shows the annual net assets of Liaoning Cheng Da Co Ltd from 1993 to 2024.

Year Net Assets Change
2024-12-31 CN¥32.38 Billion +2.40%
2023-12-31 CN¥31.62 Billion -1.88%
2022-12-31 CN¥32.23 Billion +2.39%
2021-12-31 CN¥31.48 Billion +25.88%
2020-12-31 CN¥25.01 Billion +9.01%
2019-12-31 CN¥22.94 Billion +6.15%
2018-12-31 CN¥21.61 Billion +1.13%
2017-12-31 CN¥21.37 Billion +6.82%
2016-12-31 CN¥20.00 Billion +7.05%
2015-12-31 CN¥18.69 Billion +25.50%
2014-12-31 CN¥14.89 Billion +25.68%
2013-12-31 CN¥11.85 Billion +7.21%
2012-12-31 CN¥11.05 Billion +7.69%
2011-12-31 CN¥10.26 Billion +27.17%
2010-12-31 CN¥8.07 Billion +17.49%
2009-12-31 CN¥6.87 Billion +29.34%
2008-12-31 CN¥5.31 Billion +9.89%
2007-12-31 CN¥4.83 Billion +176.80%
2006-12-31 CN¥1.75 Billion +35.57%
2005-12-31 CN¥1.29 Billion +6.21%
2004-12-31 CN¥1.21 Billion +4.01%
2003-12-31 CN¥1.17 Billion +29.55%
2002-12-31 CN¥899.86 Million +8.73%
2001-12-31 CN¥827.62 Million +12.33%
2000-12-31 CN¥736.76 Million +19.06%
1999-12-31 CN¥618.82 Million +27.49%
1998-12-31 CN¥485.38 Million +31.14%
1997-12-31 CN¥370.14 Million +40.48%
1996-12-31 CN¥263.49 Million +87.04%
1995-12-31 CN¥140.88 Million +15.04%
1994-12-31 CN¥122.46 Million +9.83%
1993-12-31 CN¥111.50 Million --

Equity Component Analysis

This analysis shows how different components contribute to Liaoning Cheng Da Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 1793188852200.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥17.93 Billion 61.20%
Common Stock CN¥1.53 Billion 5.22%
Other Comprehensive Income CN¥5.66 Billion 19.31%
Other Components CN¥4.18 Billion 14.27%
Total Equity CN¥29.30 Billion 100.00%

Liaoning Cheng Da Co Ltd Competitors by Market Cap

The table below lists competitors of Liaoning Cheng Da Co Ltd ranked by their market capitalization.

Company Market Cap
Ypsomed Holding AG
PINK:YPHDF
 		$1.40 Billion
IBF Financial Holdings Co Ltd
TW:2889
 		$1.40 Billion
Axogen Inc
NASDAQ:AXGN
 		$1.40 Billion
Shandong Shida Shenghua Chem
SHG:603026
 		$1.40 Billion
Spirent Communications plc
PINK:SPNUF
 		$1.40 Billion
Zhuhai CosMX Battery Co Ltd
SHG:688772
 		$1.40 Billion
Inmobiliaria Colonial SA
MC:COL
 		$1.40 Billion
BRAZE INC. A DL-0001
F:K43
 		$1.40 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Liaoning Cheng Da Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 28,794,321,339 to 29,299,302,070, a change of 504,980,731 (1.8%).
  • Net income of 209,556,869 contributed positively to equity growth.
  • Dividend payments of 788,933,651 reduced retained earnings.
  • Share repurchases of 50,002,562 reduced equity.
  • Other comprehensive income increased equity by 5,353,341,264.
  • Other factors decreased equity by 4,218,981,189.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥209.56 Million +0.72%
Dividends Paid CN¥788.93 Million -2.69%
Share Repurchases CN¥50.00 Million -0.17%
Other Comprehensive Income CN¥5.35 Billion +18.27%
Other Changes CN¥-4.22 Billion -14.4%
Total Change CN¥- 1.75%

Book Value vs Market Value Analysis

This analysis compares Liaoning Cheng Da Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.63x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has decreased from 146.90x to 0.63x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.08 CN¥12.17 x
1994-12-31 CN¥0.09 CN¥12.17 x
1995-12-31 CN¥0.10 CN¥12.17 x
1996-12-31 CN¥0.19 CN¥12.17 x
1997-12-31 CN¥0.26 CN¥12.17 x
1998-12-31 CN¥0.36 CN¥12.17 x
1999-12-31 CN¥0.45 CN¥12.17 x
2000-12-31 CN¥0.53 CN¥12.17 x
2001-12-31 CN¥0.60 CN¥12.17 x
2002-12-31 CN¥0.65 CN¥12.17 x
2003-12-31 CN¥0.83 CN¥12.17 x
2004-12-31 CN¥0.86 CN¥12.17 x
2005-12-31 CN¥0.91 CN¥12.17 x
2006-12-31 CN¥1.22 CN¥12.17 x
2007-12-31 CN¥3.32 CN¥12.17 x
2008-12-31 CN¥3.65 CN¥12.17 x
2009-12-31 CN¥4.76 CN¥12.17 x
2010-12-31 CN¥5.58 CN¥12.17 x
2011-12-31 CN¥7.04 CN¥12.17 x
2012-12-31 CN¥7.60 CN¥12.17 x
2013-12-31 CN¥8.16 CN¥12.17 x
2014-12-31 CN¥9.60 CN¥12.17 x
2015-12-31 CN¥11.52 CN¥12.17 x
2016-12-31 CN¥12.13 CN¥12.17 x
2017-12-31 CN¥13.10 CN¥12.17 x
2018-12-31 CN¥13.22 CN¥12.17 x
2019-12-31 CN¥14.10 CN¥12.17 x
2020-12-31 CN¥15.73 CN¥12.17 x
2021-12-31 CN¥18.30 CN¥12.17 x
2022-12-31 CN¥18.83 CN¥12.17 x
2023-12-31 CN¥18.53 CN¥12.17 x
2024-12-31 CN¥19.25 CN¥12.17 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Liaoning Cheng Da Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 0.72%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 1.86%
  • • Asset Turnover: 0.24x
  • • Equity Multiplier: 1.63x
  • Recent ROE (0.72%) is below the historical average (13.72%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 23.69% 4.06% 1.53x 3.83x CN¥15.26 Million
1994 29.39% 3.25% 2.66x 3.40x CN¥23.75 Million
1995 26.18% 3.43% 2.50x 3.05x CN¥22.44 Million
1996 16.76% 4.29% 2.00x 1.95x CN¥17.65 Million
1997 21.14% 6.68% 1.67x 1.89x CN¥38.62 Million
1998 12.56% 5.66% 1.37x 1.62x CN¥12.31 Million
1999 22.03% 10.16% 1.42x 1.53x CN¥73.24 Million
2000 24.08% 14.05% 0.96x 1.79x CN¥100.59 Million
2001 14.09% 7.60% 1.07x 1.74x CN¥32.77 Million
2002 6.84% 2.73% 1.19x 2.10x CN¥-27.53 Million
2003 3.13% 1.25% 1.19x 2.11x CN¥-76.91 Million
2004 5.22% 1.67% 1.45x 2.16x CN¥-55.28 Million
2005 7.12% 1.51% 1.82x 2.59x CN¥-35.12 Million
2006 31.32% 9.32% 1.55x 2.16x CN¥350.88 Million
2007 45.73% 38.61% 0.85x 1.40x CN¥1.65 Billion
2008 18.95% 18.35% 0.78x 1.33x CN¥443.66 Million
2009 20.67% 33.37% 0.48x 1.29x CN¥692.39 Million
2010 16.61% 24.00% 0.51x 1.35x CN¥500.82 Million
2011 23.44% 23.32% 0.67x 1.51x CN¥1.29 Billion
2012 6.71% 6.75% 0.65x 1.54x CN¥-341.28 Million
2013 7.60% 8.18% 0.58x 1.61x CN¥-267.72 Million
2014 6.04% 8.80% 0.46x 1.51x CN¥-532.80 Million
2015 2.95% 5.63% 0.34x 1.53x CN¥-1.23 Billion
2016 5.11% 10.83% 0.26x 1.79x CN¥-908.49 Million
2017 7.21% 10.33% 0.39x 1.77x CN¥-558.25 Million
2018 3.80% 4.00% 0.54x 1.77x CN¥-1.26 Billion
2019 5.51% 6.70% 0.45x 1.82x CN¥-967.78 Million
2020 11.52% 16.35% 0.43x 1.63x CN¥365.28 Million
2021 7.72% 11.75% 0.38x 1.72x CN¥-639.31 Million
2022 4.26% 8.40% 0.30x 1.68x CN¥-1.65 Billion
2023 0.81% 2.16% 0.23x 1.63x CN¥-2.65 Billion
2024 0.72% 1.86% 0.24x 1.63x CN¥-2.72 Billion

Industry Comparison

This section compares Liaoning Cheng Da Co Ltd's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

  • Industry: Medical Distribution
  • Average net assets among peers: $3,279,959,157
  • Average return on equity (ROE) among peers: 6.28%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Liaoning Cheng Da Co Ltd (600739) CN¥33.56 Billion 23.69% 0.47x $1.40 Billion
C.Q. Pharmaceutical Holding Co Ltd (000950) $2.07 Billion -17.42% 2.29x $534.66 Million
Shenzhen Glory Medical Co Ltd (002551) $2.78 Billion 3.52% 0.48x $272.16 Million
Shandong Realcan Pharmaceutical Co Ltd (002589) $5.64 Billion 0.36% 1.96x $431.85 Million
Qingdao Baheal Medical INC. (301015) $2.64 Billion 26.95% 1.01x $461.20 Million
China Meheco Co Ltd (600056) $380.35 Million 8.32% 1.39x $1.02 Billion
Jointown Pharmaceutical Group Co Ltd (600998) $8.09 Billion 6.93% 1.98x $1.61 Billion
Guangxi Liuzhou Pharm Co Ltd (603368) $1.36 Billion 15.31% 2.16x $667.23 Million